Table 2.
Demographic, Clinical, and Operative Data of the Patient Population
| Author (Year) | BMI at Diagnosis of Tumor | Years After SG (Months) | Symptom Duration(Months) | Tumor Location | Tumor Histology | Tumor Stage | Type of Treatment | Follow-Up, Mo |
|---|---|---|---|---|---|---|---|---|
| Scheepers 201113 | - | 4 | 3 | Distal esophagus | Adenocarcinoma | T2N1Mx | Chemoradiotherapy | 8mo, disease–free survival |
| Angrisani 201414 | 47 | 48 | - | Body and antrum | Signet-ring cell adenocarcinoma | pT4aN1 | Total gastrectomy, Roux-en-Y reconstruction | 8mo, disease–free survival |
| Erim 201515 | - | 48 | - | Gastric cardia | Carcinoid | - | Submucosal endoscopic dissection | - |
| Masrur 201616 | 31 | 8 | 9 | Gastroesophageal junction | Adenocarcinoma | pT4bN3a | Robot-assisted extended total gastrectomy, Roux-en-Y reconstruction | 8mo, disease–free survival |
| Sohn 201717 | 23.8 | 24 | - | Gastroesophageal junction | Adenocarcinoma | T3N0M0 | Chemotherapy + esophagogastrectomy | - |
| Vladimirov 201718 | - | 48 | 48 | Antrum | Adenocarcinoma | pT1bpN0 | Total gastrectomy, Roux-en-Y reconstruction | 24mo, disease–free survival |
| Wright 201719 | - | 60 | 33 | Distal esophagus | Adenocarcinoma | - | Chemoradiotherapy | - |
| EI Khoury 201820 | - | 36 | Several | Distal esophagus | Adenocarcinoma | PT1NO | Endoscopic mucosectomy | - |
| Sista 201821 | - | 42 | - | Pylorus | Carcinoid | - | Endoscopic radical resection | 36mo, disease–free survival |
| Seki 201822 | ≤29.3 | 12 | - | Antrum | Adenocarcinoma | pT1a | Endoscopic submucosal resection | - |
| Yamashita 201923 | - | 96 | - | Body and antrum | Signet-ring cell adenocarcinoma | pT4aN0 | Total gastrectomy with lymphadenectomy and omentectomy | 12mo, disease–free survival |
| Güzel 202024 | 28 | 36 | 2 | Body | Signet-ring cell adenocarcinoma | - | Total gastrectomy and D2 lymph node dissection | - |
| Muamar 202025 | 32.7 | 63 | 60 | Antrum | Signet-ring cell adenocarcinoma | ypT1N0 | Neoadjuvant chemotherapy+ total gastrectomy+ chemotherapy | 3mo, disease–free survival |
| Aljarboo 202026 | 42 | 48 | 4 | Gastroesophageal junction | Adenocarcinoma | pT2N1M0 | Neoadjuvant chemotherapy +distal esophagectomy and total gastrectomy with Roux-en-Y esophagojejunostomy | - |
| Genco 202027 | 33.4 | 24 | 12 | Distal esophagus | Adenocarcinoma | pT2N1M1 | Open subtotal esophagectomy with colonic interposition+ adjuvant chemotherapy | 5mo, Death |
| Genco 202027 | 70.6 | 22 | - | Gastric cardia | Adenocarcinoma | pT3N0M0 | Open subtotal esophagectomy with Roux-en-Y esophagojejunostomy= adjuvant chemotherapy | 6mo, disease–free survival |
| Genco 202027 | 25.0 | 36 | Gastroesophageal junction | Adenocarcinoma | cT3N1M1 | - | Death during completion of diagnostic assessment |